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Development and validation of the ISARIC 4C Deterioration 
model for adults hospitalised with COVID-19: a prospective 
cohort study
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Matteo Quartagno, Riinu Pius, Iain Buchan, Gail Carson, Thomas M Drake, Jake Dunning, Cameron J Fairfield, Carrol Gamble, Christopher A Green, 
Sophie Halpin, Hayley E Hardwick, Karl A Holden, Peter W Horby, Clare Jackson, Kenneth A Mclean, Laura Merson, Jonathan S Nguyen-Van-Tam, 
Lisa Norman, Piero L Olliaro, Mark G Pritchard, Clark D Russell, James Scott-Brown, Catherine A Shaw, Aziz Sheikh, Tom Solomon, Cathie Sudlow, 
Olivia V Swann, Lance Turtle, Peter J M Openshaw*, J Kenneth Baillie*, Malcolm G Semple*, Mahdad Noursadeghi*, on behalf of the ISARIC4C 
Investigators
Summary
Background Prognostic models to predict the risk of clinical deterioration in acute COVID-19 cases are urgently 
required to inform clinical management decisions.
Methods We developed and validated a multivariable logistic regression model for in-hospital clinical deterioration 
(defined as any requirement of ventilatory support or critical care, or death) among consecutively hospitalised adults 
with highly suspected or confirmed COVID-19 who were prospectively recruited to the International Severe Acute 
Respiratory and Emerging Infections Consortium Coronavirus Clinical Characterisation Consortium (ISARIC4C) 
study across 260 hospitals in England, Scotland, and Wales. Candidate predictors that were specified a priori were 
considered for inclusion in the model on the basis of previous prognostic scores and emerging literature describing 
routinely measured biomarkers associated with COVID-19 prognosis. We used internal–external cross-validation to 
evaluate discrimination, calibration, and clinical utility across eight National Health Service (NHS) regions in the 
development cohort. We further validated the final model in held-out data from an additional NHS region (London).
Findings 74 944 participants (recruited between Feb 6 and Aug 26, 2020) were included, of whom 31 924 (43·2%) of 
73 948 with available outcomes met the composite clinical deterioration outcome. In internal–external cross-validation 
in the development cohort of 66 705 participants, the selected model (comprising 11 predictors routinely measured at 
the point of hospital admission) showed consistent discrimination, calibration, and clinical utility across all eight 
NHS regions. In held-out data from London (n=8239), the model showed a similarly consistent performance 
(C-statistic 0·77 [95% CI 0·76 to 0·78]; calibration-in-the-large 0·00 [–0·05 to 0·05]); calibration slope 0·96 [0·91 to 
1·01]), and greater net benefit than any other reproducible prognostic model.
Interpretation The 4C Deterioration model has strong potential for clinical utility and generalisability to predict 
clinical deterioration and inform decision making among adults hospitalised with COVID-19.
Funding National Institute for Health Research (NIHR), UK Medical Research Council, Wellcome Trust, Department 
for International Development, Bill & Melinda Gates Foundation, EU Platform for European Preparedness Against 
(Re-)emerging Epidemics, NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at 
University of Liverpool, NIHR HPRU in Respiratory Infections at Imperial College London.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
The COVID-19 pandemic has continued to overwhelm 
health-care systems worldwide.1 Effective triage of 
patients presenting to hospital for risk of progressive 
deterioration is crucial to inform clinical decision making 
and facilitate effective resource allocation, including 
hospital beds, critical care resources, and targeted drug 
therapies. Moreover, early identification of subgroups at 
higher risk of death or deterioration requiring ventilatory 
or critical care support enables targeted recruitment for 
randomised controlled trials of therapies with equipoise,2 
and more precise delivery of treatments for which 
effectiveness is known to vary according to disease 
severity (including corticosteroids and remdesivir).3–5
Many multivariable clinical prognostic models for 
patients with COVID-19 have rapidly accrued to predict 
adverse outcomes of mortality or clinical deterioration.6 
Most have been classified as being at a high risk of bias, 
and might not be generalisable, often because of 
inadequate sample sizes, reliance on single-centre data, 
and non-adherence to best practice methods or reporting 
standards during model development.6,7 None of the 
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multivariable prognostic models included in a systematic 
head-to-head external validation study outperformed 
univariable predictors,8 highlighting the need to combine 
large scale multisite data with rigorous model develop-
ment methods to improve generalisability.
We previously reported a pragmatic prognostic score 
for in-hospital mortality from the International Severe 
Acute Respiratory and Emerging Infections Consortium 
Coronavirus Clinical Characterisation Consortium 
(ISARIC4C) study.9 In this Article, we extend this work 
through a larger study cohort to develop and validate a 
prognostic model for in-hospital clinical deterioration 
(requirement for ventilatory support or critical care, or 
death). We use the wide geographical coverage of the 
ISARIC4C study cohort in England, Wales, and Scotland 
to explore between-region heterogeneity and to compre-
hensively assess model generalisability with respect to 
discrimination, calibration, and clinical utility. We have 
called this the 4C Deterioration model.
Methods
Study population and data collection
The International Severe Acute Respiratory and 
Emerging Infections Consortium (ISARIC)–WHO 
Clinical Characterisation Protocol UK (CCP-UK) study 
is being conducted by the ISARIC4C in 260 hospitals 
across England, Scotland, and Wales (National Institute 
for Health Research [NIHR] Clinical Research Network 
Central Portfolio Management System ID 14152).10 In 
this analysis, we included consecutive adults (aged 
≥18 years) who had highly suspected or PCR-confirmed 
COVID-19. We included patients with suspected 
COVID-19 in the analysis because the model is intended 
for use in participants at the point of initial evaluation 
for COVID-19, when virological confirmation might not 
be available. The study is reported in accordance with 
Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis (TRIPOD) 
guidance.11 Demographic, clinical, and outcome data 
were collected through a publicly available standardised 
case record form, as reported previously.9,10
Ethical approval was given by the South Central 
Oxford C research ethics committee in England (reference 
13/SC/0149), and by the Scotland A research ethics 
committee (reference 20/SS/0028). The study is registered 
with ISRCTN (ISRCTN66726260).
Outcomes
We used a composite primary outcome of in-hospital 
clinical deterioration, comprising any of the following: 
initiation of ventilatory support (non-invasive ventilation, 
invasive mechanical ventilation, or extracorporeal mem-
brane oxygenation); admission to a high-dependency or 
intensive care unit; or death. This outcome aligns closely 
with a score of 6 or higher on the WHO Clinical 
Progression Scale12 and ensures that the outcome is 
generalisable between hospitals, since respiratory support 
practices can vary considerably. We included eligible 
Research in context
Evidence before this study
An existing systematic review evaluated prediction models for 
COVID-19 indexed in PubMed, Embase, arXiv, medRxiv, and 
bioRxiv up to May 5, 2020. 145 models were identified, 50 of 
which were prognostic models seeking to predict clinical 
outcomes of mortality or clinical deterioration. The proposed 
models were considered to be poorly reported, at high risk of 
bias, and their reported performance was thought to be 
overestimated. A systematic head-to-head external validation 
study of 22 of these prognostic models found that none had 
clinical utility over and above simple univariable predictors of 
age for mortality and oxygen saturation for clinical 
deterioration. Thus, none of the multivariable models could be 
recommended for clinical implementation, highlighting a need 
for higher quality model development methodology using 
multicentre datasets to maximise generalisability.
Added value of this study
We developed and validated the 4C Deterioration model, 
including 11 routinely measured demographic, clinical, and 
laboratory predictors, for prediction of in-hospital clinical 
deterioration among 74 944 consecutive adults recruited to 
the ISARIC4C study across 260 hospitals in England, 
Scotland, and Wales, in accordance with TRIPOD standards. 
The 4C Deterioration model showed consistent discrimination, 
calibration, and net benefit across eight National Health Service 
regions during model development, with similar performance 
in held-out validation data from London. Importantly, the 
4C Deterioration model suggested clinical utility with higher 
net benefit than other reproducible candidate models in a 
decision-curve analysis in all regions. In comparison to our 
recently reported 4C Mortality Score, 4C Deterioration offers 
significant additional value by identifying people at high risk of 
deterioration despite a low risk of mortality, with potential to 
better target interventions for those who need them and are 
most likely to benefit.
Implications of all the available evidence
Parallel prognostic models are required for the prediction of a 
composite outcome of clinical deterioration and of mortality 
alone among hospitalised adults with COVID-19. The 
4C Deterioration model shows stronger potential for clinical 
utility and generalisability than any previous prognostic model 
for clinical deterioration among adults with COVID-19. The 
model parameters and risk prediction tool will be made freely 
available online alongside our previously reported 4C Mortality 
Score to enable independent external validation and facilitate 
risk stratification for therapeutic interventions.
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participants admitted or first assessed for COVID-19 on 
or before Aug 26, 2020, to allow at least a 4-week interval 
for registration of outcome events before the final data 
extraction date (Sept 24, 2020). Participants who had 
ongoing hospital care at the end of follow-up (the point at 
which a final outcome was recorded in the case record 
form) were classified as not meeting the endpoint because 
the risk of deterioration declines with time since 
admission.8
Candidate predictors
We included candidate predictors considered in our 
previous development and validation of the 4C Mortality 
Score9 that were available in at least 60% of the study 
population (appendix p 21). These predictors were 
specified a priori on the basis of previous prognostic 
scores and emerging literature describing routinely 
measured biomarkers associated with COVID-19 
prognosis.9 We also included nosocomial COVID-19 
acquisition to test the hypothesis that acquisition of 
infection in hospital might be associated with differential 
risk. Community-acquired infection was defined as 
symptom onset or first positive severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) PCR result 
within 7 days from admission; participants who did not 
meet these criteria and had either symptom onset or 
first positive SARS-CoV-2 PCR result more than 7 days 
from admission were classified as nosocomial cases.13 
Among nosocomial cases, patients who met the 
deterioration outcome before the onset of COVID-19 
were excluded.
Comorbidities were defined according to a modified 
Charlson comorbidity index,14 with the addition of 
clinician-defined obesity.9 We considered a composite 
variable representing number of comorbidities for 
inclusion in the model, which comprised the following 
comorbidities: chronic cardiac disease, chronic respiratory 
disease (excluding asthma), chronic renal disease, mild to 
severe liver disease, dementia, chronic neurological 
disease, connective tissue disease, diabetes, HIV or AIDS, 
malignancy, and clinician-defined obesity.
All predictors were taken from the day of hospital 
admission or the day of first clinical suspicion of 
COVID-19 for nosocomial cases. 
Model development
We hypothesised that heterogeneity among populations 
and health-care services between geographical regions 
might contribute to differences in model performance. 
Therefore, we divided the data into nine National Health 
Service (NHS) regions15 linked to contributing hospitals. 
Eight regions were used in model development and 
internal–external cross-validation (East of England, the 
Midlands, North East England and Yorkshire, North West 
England, Scotland, South East England, South West 
England, and Wales) as described below. The ninth 
region (London) was not used in model development but 
was held out for further validation, independent of the 
model training cohort.
We used a logistic regression modelling approach in 
view of the short time horizon for predictions (during 
hospital admission) and did backward elimination of the 
a priori candidate variables in the development cohort 
(appendix p 5). Continuous predictors were modelled 
with restricted cubic splines using a default of four knots, 
placed at recommended locations based on percentiles, 
by generating transformations using the rcs function in 
the rms package in R.16,17 Glasgow coma scale scores were 
categorised as 15 or less than 15 because there were 
insufficient datapoints below 15 to fit spline functions. 
We used multiple imputation with chained equations to 
address missing data; analyses were done in each 
imputed dataset and pooled using Rubin’s rules in the 
primary analysis (appendix p 5).18
Model validation
During validation, we assessed model discrimination 
(how well predictions differentiated participants who 
experienced the composite outcome from those who did 
not, quantified as the C-statistic), calibration (agreement 
between predicted and observed risk, assessed using 
calibration slopes, calibration-in-the-large, and calibration 
plots) and clinical utility (quantified as net benefit).19 An 
ideal calibration slope is 1, while calibration-in-the-large 
should be 0 if the number of observed outcome events 
matches the number predicted.
The model including the selected variables was first 
validated in the development dataset using the internal–
external cross-validation framework to concurrently 
examine between-region heterogeneity and assess 
generalisability.19,20 In this process, each of the eight 
contributing NHS regions was iteratively excluded 
from the development set; the model was then trained 
using the selected predictors in the remaining regions 
and validated in the omitted region by quantifying the 
C-statistic, calibration slope, and calibration-in-the-
large, and by visualisation of calibration plots (appendix 
p 5).19 We used random-effects meta-analysis to calculate 
pooled C-statistics, calibration slopes, and calibration-
in-the-large statistics across development regions, and 
forest plots were examined to assess between-region 
heterogeneity.
The final model was then trained using the full 
development dataset and further validated in the held-
out NHS region (London).
Decision curve analysis allows assessment of clinical 
utility by quantifying the trade-off between correctly 
identifying true positives and incorrectly identifying false 
positives weighted according to the threshold probability.21 
The threshold probability represents the risk cutoff above 
which any given treatment or intervention might be 
considered, and reflects the perceived risk:benefit ratio 
for the intervention. Decision curve analysis was used in 
internal–external validation and held-out validation to 
See Online for appendix
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Overall (n=74 944) Ventilatory support or 
HDU or ICU admission 
(n=15 039)
Death (n=16 885) No deterioration 
(n=42 024)
Missing (n=996)
Age, years 75 (60–84) 65 (55–75) 83 (77–89) 73 (57–83) 75 (59–84)
Sex
Female 32 807 (43·9%) 5127 (34·1%) 7106 (42·2%) 20 141 (48·0%) 433 (43·5%)
Male 41 993 (56·1%) 9889 (65·9%) 9742 (57·8%) 21 800 (52·0%) 562 (56·5%)
Missing 144 23 37 83 1
Ethnicity
White 55 016 (82·8%) 9941 (75·0%) 13 612 (89·5%) 30 854 (83·0%) 609 (79·2%)
South Asian 3520 (5·3%) 1010 (7·6%) 479 (3·2%) 1992 (5·4%) 39 (5·1%)
Black 2553 (3·8%) 743 (5·6%) 345 (2·3%) 1435 (3·9%) 30 (3·9%)
East Asian 492 (0·7%) 162 (1·2%) 71 (0·5%) 255 (0·7%) 4 (0·5%)
Other 4844 (7·3%) 1403 (10·6%) 698 (4·6%) 2656 (7·1%) 87 (11·3%)
Missing 8519 1780 1680 4832 227
SARS-CoV-2 PCR positive 66 136 (96·9%) 13 153 (96·1%) 15 275 (98·2%) 37 106 (96·7%) 602 (97·6%)
Missing data 6715 1346 1325 3665 379
Number of comorbidities 1 (1–2) 1 (0–2) 2 (1–3) 1 (0–2) 1 (0–2)
Missing data 839 68 202 406 163
Nosocomial infection 7320 (9·9%) 541 (3·6%) 2093 (12·5%) 4542 (10·9%) 144 (16·6%)
Missing data 644 64 101 351 128
Radiographic infiltrates 29 579 (61·9%) 8417 (76·9%) 6960 (63·5%) 14 015 (55·0%) 187 (53·7%)
Missing data 27 195 4094 5920 16 533 648
Temperature, °C 37·2 (36·5–38·1) 37·5 (36·8–38·4) 37·1 (36·4–38·0) 37·1 (36·5–38·0) 37·0 (36·5–38·0)
Missing data 3106 462 647 1783 214
Heart rate, per min 90 (78–104) 95 (82–109) 90 (77–105) 88 (76–102) 89 (79–102)
Missing data 3383 422 717 2021 223
Respiratory rate, breaths per min 20 (18–26) 24 (20–30) 22 (18–28) 20 (18–24) 20 (18–24)
Missing data 3535 483 687 2113 252
Systolic blood pressure, mm Hg 130 (114–147) 129 (115–145) 128 (110–147) 130 (115–147) 130 (114–148)
Missing data 3187 426 648 1891 222
Diastolic blood pressure, mm Hg 74 (64–84) 74 (65–83) 71 (61–82) 75 (65–84) 73 (65–83)
Missing data 3330 458 690 1955 227
Oxygen saturation, % 95 (92–97) 94 (89–96) 95 (91–97) 96 (94–97) 96 (93–98)
Missing data 3756 537 799 2203 217
Room air or oxygen
Room air 48 574 (69·4%) 7213 (50·3%) 9978 (63·1%) 30 809 (78·7%) 574 (76·4%)
Oxygen 21 453 (30·6%) 7128 (49·7%) 5824 (36·9%) 8324 (21·3%) 177 (23·6%)
Missing data 4917 698 1083 2891 245
Glasgow coma scale 15 (15–15) 15 (15–15) 15 (15–15) 15 (15–15) 15 (15–15)
Missing data 7839 1759 1693 4020 367
Haemoglobin, g/L 128 (112–142) 132 (116–145) 122 (105–138) 129 (113–142) 128 (112–141)
Missing data 11 748 1398 2562 7448 340
White cell count, × 10⁹ cells per L 7·5 (5·4–10·7) 8·0 (5·7–11·2) 8·3 (5·8–11·9) 7·1 (5·2–9·9) 7·7 (5·4–10·7)
Missing data 12 130 1491 2669 7623 347
Lymphocytes, × 10⁹ cells per L 0·90 (0·60–1·30) 0·80 (0·60–1·20) 0·80 (0·50–1·16) 0·96 (0·67–1·40) 0·90 (0·60–1·30)
Missing data 12345 1535 2700 7763 347
Neutrophils, × 10⁹ cells per L 5·8 (3·9–8·7) 6·4 (4·3–9·3) 6·6 (4·3–9·9) 5·3 (3·6–7·9) 5·8 (3·7–8·7)
Missing data 12 308 1533 2702 7726 347
Platelets, × 10⁹ cells per L 221 (167–290) 219 (166–287) 209 (154–284) 226 (173–294) 218 (161–285)
Missing data 12 463 1538 2730 7847 348
Alanine aminotransferase, IU/L 25 (16–43) 33 (21–54) 22 (15–37) 24 (15–40) 24 (15–43)
Missing data 26 735 3861 6289 16 085 500
(Table 1 continues on next page)
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quantify the net benefit of implementing the model in 
clinical practice,21 compared with the following: a treat-all 
approach; a treat-none approach; and using other COVID-
19-specific and pre-existing prognostic models identified 
by recent systematic reviews.6,8,9 We included all models in 
which constituent variables were available in more than 
60% of the cohort. Candidate models using points scores 
were calibrated to the validation data during decision-
curve analysis, resulting in optimistic estimates of their 
net benefit. All decision curves were smoothed by locally 
weighted smoothing (LOESS) from stacked multiply 
imputed datasets.19
All analyses were done in R (version 3.6.3; appendix 
p 6).
Sensitivity analysis
We assessed validation of the final model using 
complete case data only in the held-out NHS region. We 
also recalculated validation metrics when stratifying 
deterioration events by time to deterioration (on vs 
after day of admission or first COVID-19 assessment; and 
0–3 days vs >3 days after admission or first COVID-19 
assessment), to assess whether discrimination varied 
according to time interval to the outcome; when excluding 
participants in the validation cohort who had ongoing 
hospital care at the end of follow-up; when stratifying 
the validation cohort by community versus nosocomial 
infection; and when excluding community-acquired cases 
in which patients developed symptoms in the interval 
between admission and the temporal threshold for 
nosocomial infection, to assess any effect of incorrect 
inclusion of nosocomial infections within the community-
acquired cases. We also repeated the analysis with 
an alternative multiple imputation approach, using the 
aregImpute function from the rms package in R,17 and 
recalculated model parameters using alternative temporal 
definitions of nosocomial SARS-CoV-2 infection. Finally, 
we assessed the discrimination of each of the continuous 
variables included in the final model as single univariable 
predictors.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results 
Between Feb 6 and Aug 26, 2020, 74 944 eligible adults 
were recruited to the ISARIC4C study, of whom 
66 136 (88·2%) were known to have PCR-confirmed 
Overall (n=74 944) Ventilatory support or 
HDU or ICU admission 
(n=15 039)
Death (n=16 885) No deterioration 
(n=42 024)
Missing (n=996)
(Continued from previous page)
Bilirubin, mg/dL 10 (7–14) 10 (7–15) 10 (7–15) 9 (6–13) 10 (7–14)
Missing data 22 931 3107 5308 14 025 491
Urea, mmol/L 7 (5–11) 7 (5–11) 10 (7–16) 6 (4–9) 7 (5–12)
Missing data 18 509 2761 3965 11 344 439
Creatinine, µmol/L 86 (67–121) 86 (68–118) 106 (76–158) 81 (64–107) 85 (68–122)
Missing data 12 656 1609 2699 7998 350
Sodium, mmol/L 137 (134–140) 136 (133–139) 138 (135–143) 137 (134–140) 137 (134–140)
Missing data 12 277 1491 2623 7810 353
C-reactive protein, mg/L 80 (33–154) 126 (64–210) 98 (48–174) 58 (22–119) 76 (30–151)
Missing data 16 318 2198 3508 10 202 410
NHS region
East of England 7852 (10·5%) 1640 (10·9%) 1935 (11·5%) 4223 (10·0%) 54 (5·4%)
London 8239 (11·0%) 2275 (15·1%) 1509 (8·9%) 4400 (10·5%) 55 (5·5%)
Midlands 15 583 (20·8%) 2547 (16·9%) 3699 (21·9%) 9068 (21·6%) 269 (27·0%)
North East and Yorkshire 10 305 (13·8%) 2233 (14·8%) 2223 (13·2%) 5773 (13·7%) 76 (7·6%)
North West 12 914 (17·2%) 2170 (14·4%) 3290 (19·5%) 7311 (17·4%) 143 (14·4%)
Scotland 3066 (4·1%) 605 (4·0%) 572 (3·4%) 1846 (4·4%) 43 (4·3%)
South East 9445 (12·6%) 2130 (14·2%) 1971 (11·7%) 5051 (12·0%) 293 (29·4%)
South West 3915 (5·2%) 723 (4·8%) 794 (4·7%) 2361 (5·6%) 37 (3·7%)
Wales 3625 (4·8%) 716 (4·8%) 892 (5·3%) 1991 (4·7%) 26 (2·6%)
Data are median (IQR) or n (%), calculated from non-missing data. Participants are shown by the first chronological deterioration category through which they met the 
composite primary outcome (HDU or ICU admission, ventilatory support, or death). HDU=high-dependency unit. ICU=intensive care unit. SARS-CoV-2=severe acute 
respiratory syndrome coronavirus 2. NHS=National Health Service.
Table 1: Baseline characteristics of the study cohort, stratified by outcome
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COVID-19. Baseline demographic, physiological, and 
laboratory characteristics are shown stratified by 
outcome (table 1) and by community versus nosocomial 
infection (appendix p 22). Outcomes were missing for 
996 (1·3%) participants. Of the 73 948 participants with 
outcomes available, the composite primary outcome 
of in-hospital clinical deterioration was met by 
31 924 (43·2%), with a median time to deterioration of 
4 days (IQR 1–9; appendix p 7). Risk of deterioration 
declined with increasing time from admission, 
supporting our approach to classify patients requiring 
ongoing hospital care at the end of follow-up as not 
meeting an endpoint in the primary analysis.
66 705 participants from eight regions (with sample 
sizes ranging from 3066 to 15 583) were included in 
model development, with a further 8239 from one region 
(London) held out for additional validation. Candidate 
predictors and their proportions of missingness, stratified 
by NHS region, are shown in the appendix (p 8). 
Proportions of missingness were similar across regions 
for each variable.
In backward elimination, 11 predictors were retained 
in more than five (>50%) of ten multiply imputed 
datasets in more than four (>50%) of eight development 
NHS regions, and entered the final model. These 
predictors were age, sex, nosocomial infection, Glasgow 
coma scale score, peripheral oxygen saturation (SpO2) at 
admission, breathing room air or oxygen therapy 
(contemporaneous with SpO2 measurement), respiratory 
rate, urea concentration, C-reactive protein concen-
tration, lymphocyte count, and presence of radiographic 
chest infiltrates. Associations (including non-linearities) 
between each predictor and the outcome from the final 
4C Deterioration model trained on the full development 
cohort are shown in figure 1, and full model coefficients 
are presented in the appendix (p 23) to enable 
independent model reconstruction.
Forest plots showing model discrimination (C-statistic) 
and calibration metrics (slope and calibration-in-the-large) 
from internal–external cross-validation20 of the prognostic 
model in the development cohort are shown in figure 2. 
C-statistics were consistent across development NHS 
regions (point estimates 0·75 to 0·77; pooled random-
effects meta-analysis estimate 0·76 [95% CI 0·75 to 0·77]). 
Calibration slopes were also consistent across regions, 
with little evidence of heterogeneity (point estimates 0·95 
to 1·06; pooled estimate 0·99 [0·97 to 1·02]). There was 
minor heterogeneity across NHS regions in calibration-in-
the-large, probably reflecting some variation in baseline 
risk between regions (point estimates –0·19 to 0·15; 
pooled estimate –0·01 [–0·12 to 0·09]). Overall risk 
was slightly underestimated in South East England 
(calibration-in-the-large 0·09 [95% CI 0·05 to 0·14]) and 
Wales (0·15 [0·07 to 0·22]), and overestimated in Scotland 
(–0·19 [–0·28 to –0·11]) and South West England (–0·19 
[–0·26 to –0·11]). Pooled calibration plots by NHS region 
are shown in the appendix (p 9). In view of the minor 
variation in calibration-in-the-large between NHS regions, 
we also repeated internal–external cross-validation with 
recalibration to each NHS region by re-estimation of 
the model intercept; calibration plots with recalibrated 
intercepts confirmed small improvements in model 
calibration (appendix p 10).
Decision-curve analyses in the validation sets from 
internal–external cross-validation, without recalibration 
of the new model, are shown in the appendix (p 11), with 
benchmarking to 11 existing candidate prognostic 
models for which the constituent variables were 
Figure 1: Multivariable associations between selected predictors and outcome in final model
Variable selection was done in each imputed dataset with backward elimination within each National Health 
Service region (appendix p 5). Black lines and dots indicate point estimates; red shaded regions and error bars 
indicate 95% CIs.
Respiratory rate (per min) Oxygen saturation (%) Urea concentration (mmol/L)
Age (years) C-reactive protein (mg/L) Lymphocyte count 
×10⁹ cells per L
15 20 25 30 35 40 70 80 90 100 0 10 20 30 40

























Room air or oxygen Sex
Glasgow coma scale Nosocomial infection Radiographic infiltrates
Oxygen Room air Female Male





























































www.thelancet.com/respiratory   Published online January 11, 2021   https://doi.org/10.1016/S2213-2600(20)30559-2 7
available in more than 60% of participants. The 
4C Deterioration model had higher net benefit than any 
of the existing models and the treat-all or treat-none 
strategies across a broad range of threshold probabilities 
in all development NHS regions (without local 
recalibration).
Subsequently, we validated the final prognostic model, 
trained on the full development cohort, in the held-out 
NHS region. Discrimination and calibration metrics for 
the 4C Deterioration model were similar to the estimates 
from internal–external cross-validation (table 2), with 
C-statistic 0·77 (0·76 to 0·78), calibration-in-the-large 0·00 
(–0·05 to 0·05), and calibration slope 0·96 (0·91 to 1·01; 
visual calibration curve shown in figure 3A). Discrimination 
was higher for the 4C Deterioration model than for the 
other existing candidates. The sensitivity, specificity, 
positive-predictive value, and negative-predictive value 
across the full range of probability thresholds from the 
model are shown in the appendix (p 12).
Decision-curve analysis in the held-out NHS region to 
further examine clinical utility for the 4C Deterioration 
model showed higher net benefit than all other 
candidates and the treat-all and treat-none approaches 
across a range of threshold probabilities (figure 3B).
We anticipate that clinicians might wish to evaluate 
risk of deterioration or death separately. Therefore, 
for illustration, we compared predictions from the 
4C Deterioration model to our previously reported 
4C Mortality Score9 in the London validation cohort, 
stratified by age (figure 4A), sex, and ethnicity (appendix 
p 13). In addition, ten example participants selected at 
random from each decile of 4C Deterioration predictions 
in the London cohort are shown in figure 4B, with their 
clinical characteristics summarised in figure 4C. Overall, 
deterioration predictions appeared appropriately higher 
than those for mortality. Importantly, the covariance 
between 4C Mortality Score and 4C Deterioration 
predictions was lower among younger age groups, 
among whom discrepancies between predictions were 
therefore greater. There were no differences in covariance 
by sex or ethnicity after stratification by age.
Validation of the model in complete case data from the 
held-out London region showed similar results to the 
primary analyses (appendix p 24). Stratification of 
outcome events (on vs after day of admission or first 
COVID-19 assessment; and 0–3 days vs >3 days after 
admission or first COVID-19 assessment) in the London 
validation cohort resulted in slightly lower C-statistics 
with longer time horizons for the 4C Deterioration model 
and most other models (appendix p 26). However, for 
some models in which mortality was the original 
intended outcome (including the 4C Mortality model), 
discrimination appeared better over the longer time 
Original outcome* C-statistic Calibration-in-the-
large
Slope
4C Deterioration Deterioration 
(in-hospital)
0·77 (0·76 to 0·78) 0·00 (–0·05 to 0·05) 0·96 (0·91 to 1·01)
NEWS222 Deterioration (1 day) 0·69 (0·68 to 0·70) ·· ··
4C Mortality9 Mortality (in-hospital) 0·68 (0·67 to 0·69) ·· ··
DL-Death23 Mortality (in-hospital) 0·67 (0·66 to 0·69) 2·24 (2·18 to 2·30) 0·14 (0·10 to 0·18)
DL-Poor23 Deterioration 
(in-hospital)
0·67 (0·66 to 0·68) 0·53 (0·47 to 0·59) 0·13 (0·10 to 0·16)
REMS24 Mortality (in-hospital) 0·66 (0·65 to 0·68) ·· ··
DS CRB-6525 Mortality (30 days) 0·66 (0·65 to 0·67) ·· ··
A-DROP26 Mortality (30 days) 0·65 (0·64 to 0·66) ·· ··
CURB-6527 Mortality (30 days) 0·65 (0·64 to 0·66) ·· ··
MEWS28 Deterioration 
(in-hospital)
0·63 (0·62 to 0·64) ·· ··
qSOFA29 Mortality (in-hospital) 0·63 (0·62 to 0·64) ·· ··
ACP Index30 Mortality (12 days) 0·62 (0·61 to 0·63) ·· ··
Models are shown for prediction of in-hospital clinical deterioration and are sorted by C-statistic (total sample size 
8239 participants). Calibration-in-the-large and slopes are not shown for points score models because they are not on 
a probability scale. NEWS2=National Early Warning Score 2. REMS=Rapid Emergency Medicine Score. MEWS=Modified 
Early Warning Score. qSOFA=quick Sequential Organ Failure Assessment. ACP=Age and C-reactive Protein. *Original 
intended outcome for each candidate model during development.
Table 2: Validation performance in held-out London region
0·7 0·72 0·75 0·78 0·8
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Wales (n=3625)
Meta-analysis
0·76 (0·75 to 0·77)
0·76 (0·75 to 0·77)
0·77 (0·76 to 0·78)
0·76 (0·75 to 0·77)
0·76 (0·75 to 0·78)
0·75 (0·74 to 0·76)
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 −0·19 (−0·28 to −0·11)
  0·09 ( 0·05 to 0·14)
 −0·19 (−0·26 to −0·11)
  0·15 ( 0·07 to 0·22)
 −0·01 (−0·12 to 0·09)
0·8 0·9 1 1·1 1·2
0·99 (0·93 to 1·05)
1·00 (0·96 to 1·04)
1·06 (1·01 to 1·11)
0·99 (0·95 to 1·03)
0·97 (0·88 to 1·06)
0·95 (0·90 to 1·01)
0·98 (0·90 to 1·07)
0·98 (0·89 to 1·07)
0·99 (0·97 to 1·02)







Figure 2: Internal–external cross-validation of selected model by National Health Service region
Dashed lines indicate lines of perfect calibration-in-the-large (0) and calibration slope (1). Black squares indicate point estimates; bars indicate 95% CIs; diamonds indicate pooled estimates from a 
random-effects meta-analysis (n=66 705).
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horizons. Validation metrics in the London cohort were 
similar to those of the primary analysis when excluding 
participants who had ongoing hospital care at the end 
of follow-up (appendix p 27), when restricted to 
community-acquired infections (appendix p 28), and 
when community-acquired infections with symptom 
onset after admission were excluded (appendix p 29). 
Among nosocomial cases, the C-statistic was slightly 
lower for the 4C Deterioration model than for the primary 
analysis (0·73 [0·68 to 0·78]), although discrimination 
remained higher than that of the other candidate models, 
and calibration-in-the-large was 0·32 (0·12 to 0·53), 
suggesting elevated baseline risk among participants 
with nosocomial infection (appendix p 28). Repeating the 
analyses with use of an alternative multiple-imputation 
approach and with shorter and longer temporal defini-
tions of nosocomial infection led to similar results to the 
primary analysis (appendix pp 14–19, 30). Of the 
continuous variables in the final model, serum C-reactive 
protein concentration was the strongest univariable 
predictor for deterioration (C-statistic 0·68 [0·66 to 0·69]) 
but had lower discrimination than the full multivariable 
model (appendix p 31).
Discussion
We developed and validated a prognostic model for in-
hospital clinical deterioration among 74 944 consecutive 
adults hospitalised with COVID-19 and recruited to the 
ISARIC4C study across 260 hospitals in England, 
Scotland, and Wales. The final model integrates 
11 routinely available predictors and is intended for use at 
the point of admission for community-acquired cases, or 
first evaluation of suspected nosocomial COVID-19. 
Internal–external cross-validation showed consistent 
discrimination, calibration, and net benefit across NHS 
regions, which were confirmed in further validation 
in the held-out London region. The model provides 
a probability output that indicates the chance of the 
individual under evaluation having the outcome. These 
predictions will enable clinicians to objectively assess 
deterioration risk to inform the need for interventions 
such as ongoing hospital admission, consideration 
for critical care, and initiation of therapeutic agents. 
Importantly, the 4C Deterioration model achieved higher 
net benefit than other candidate risk-stratification tools 
across a broad range of risk thresholds in all NHS 
regions. Thus, the 4C Deterioration model has strong 
potential for clinical utility and generalisability.
Our 4C Deterioration model can be implemented 
programmatically alongside our previously reported 
4C Mortality Score.9 Covariance between the 4C 
Deterioration and 4C Mortality predictions was not 
systematically different by sex or ethnicity, but was 
attenuated among younger age groups. Thus, the greatest 
discordance of risks is evident in younger patients. This 
finding suggests that younger people who deteriorated 
were more likely to have escalation of treatment through 
admission to a high-dependency or intensive care unit or 
through ventilatory support, whereas older people who 
deteriorated were more likely to die. These observations 
might be mediated, in part, by differential treatment 
escalation decisions associated with age. Moreover, our 
comparison of the models for ten randomly selected 
patients across the distribution of outcome risks 
illustrates examples of cases with relatively low risks of 
death, but moderate to high risks of deterioration. These 
Figure 3: Calibration and decision-curve analysis in held-out London region (n=8239)
(A) Calibration is shown using locally weighted smoothing (LOESS) across multiply imputed datasets. (B) Net benefit is shown with LOESS for each candidate model 
compared with the treat-all and treat-none approaches. Points score models are recalibrated to the validation data, resulting in optimistic estimates of net benefit for 
these models. NEWS2=National Early Warning Score 2. REMS=Rapid Emergency Medicine Score. MEWS=Modified Early Warning Score. qSOFA=quick Sequential Organ 
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discordances underline the need for parallel prognostic 
models for a composite outcome of clinical deterioration 
and for mortality alone. Notably, the discrimination of 
the 4C Deterioration declined slightly with increasing 
time to outcome events, whereas that of the 4C Mortality 
model improved, probably reflecting the fact that most 
deterioration events that occurred more than 3 days after 
admission were deaths, whereas earlier events were 
more likely to be initiations of ventilatory support or 
high-dependency or intensive care. Application of the 
4C Mortality Score and 4C Deterioration model together 
therefore provides the optimal approach for clinicians to 
predict the appropriate outcome as required to inform 
clinical management decisions.
We overcame the weaknesses of previous COVID-19 
predictive models6,8 by adhering to TRIPOD standards11 
and retaining continuous variables without arbitrary 
categorisation, while accounting for non-linear associa-
tions, to avoid loss of information.31 Moreover, we used the 
largest dataset to date, to our knowledge, to develop and 
validate the 4C Deterioration model, reducing the risk of 
overfitting due to inadequate sample size. We exploited 
the wide geographical coverage across nine NHS regions 
in England, Scotland, and Wales to explore between-
region heterogeneity in model performance using 
internal–external cross-validation.32 Although discrim-
ination, calibration slopes, and net benefit were largely 
very consistent, we noted minor variation in calibration-
in-the-large, suggesting some variation in baseline risk 
between regions. Our approach of recalibrating the model 
intercept to each NHS region showed the potential to 
address such heterogeneity and could be used to update 
the model if risk changes temporally (as novel therapies 
are implemented) and among different populations. 
Nonetheless, net benefit, which accounts for model 
discrimination and calibration in quantifying clinical 
utility, was higher for the 4C Deterioration model than for 
all other candidates, even without recalibration, across all 
NHS regions and in the held-out validation dataset. This 
was the case even when comparing to points-based 
models, which might have achieved overly optimistic 
performance in decision-curve analyses because they were 
recalibrated to the validation datasets. We also used a best-
practice approach to missing data with multiple 
imputation,33 and obtained consistent results with an 
alternative imputation approach.
Our 4C Deterioration model was developed and 
validated in the context of current care; predictions should 
therefore be interpreted as reflecting both baseline risk 
and potential mitigation through in-hospital interventions. 
Ongoing prospective external validation of the 4C 
Deterioration model will be required to consider the need 
for temporal recalibration34 and to evaluate model 
performance in diverse international settings outside of 
the ISARIC4C study. Although the model showed 
consistent performance across England, Wales, and 
Scotland, validation in other counties should be prioritised 
Figure 4: 4C Deterioration versus 4C Mortality predictions for London 
validation cohort (n=8239) and randomly sampled example patients (n=10)
4C Mortality probabilities are calculated from points scores, based on observed 
mortality risk for each score in the original validation data. (A) Smoothed plot 
reflects locally estimated scatterplot smoothing fit, stratified by age (<50 years, 
50–69 years, or ≥70 years), in the London cohort (n=8239). (B) Ten example 
patients were randomly sampled from the validation cohort, stratified by deciles 
of 4C Deterioration model predictions. (C) Characteristics of each example 
participant, with red indicating characteristics associated with higher risk 
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to enable its clinical implementation internationally. We 
have provided the underlying model coefficients to enable 
this. Another limitation is that we only included predictors 
that were routinely measured as part of clinical care 
during the study period, and specified that they had to be 
available among more than 60% of the population for 
inclusion in the analysis. Thus, we were unable to assess 
candidate models that include predictors such as lactate 
dehydrogenase or D-dimer concentrations, because these 
variables were only available in a small proportion of 
participants. Future studies could consider standardised 
capture of laboratory measurements considered to have 
prognostic value to enable inclusion of these variables in 
model development and validation at scale. Moreover, we 
note that novel molecular biomarkers currently under 
investigation might also offer prognostic value.35 Blood 
transcript, protein, and metabolite measurements will be 
available from a subset of the ISARIC4C participants and 
could be integrated into risk-stratification tools in future 
studies.
In summary, we present a prognostic model for clinical 
deterioration among hospitalised adults with community-
acquired or hospital-acquired COVID-19, validated in 
nine NHS regions in England, Scotland, and Wales. The 
model uses readily available clinical predictors to predict 
the probability of in-hospital deterioration and will be 
made freely available online alongside our previously 
reported mortality risk score,9 to inform clinical decision 
making and patient stratification for therapeutic 
interventions.
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